^Dajas-Bailador FA, Asencio M, Bonilla C, Scorza MC, Echeverry C, Reyes-Parada M, Silveira R, Protais P, Russell G, Cassels BK, Dajas F (March 1999). "Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission". General Pharmacology. 32 (3): 373–9. doi:10.1016/s0306-3623(98)00210-9. PMID10211594.
^Valiente M, D'Ocon P, Noguera MA, Cassels BK, Lugnier C, Ivorra MD (July 2004). "Vascular activity of (-)-anonaine, (-)-roemerine and (-)-pukateine, three natural 6a(R)-1,2-methylenedioxyaporphines with different affinities for alpha1-adrenoceptor subtypes". Planta Medica. 70 (7): 603–9. doi:10.1055/s-2004-827181. PMID15254852. S2CID260249660.
^Aston BC (1909). "The Alkaloids of the Pukatea". Transactions of the Royal Society of New Zealand. 42. Retrieved October 20, 2015.